LUNG NON-SMALL CELL CARCINOMA
Clinical trials for LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy boosts radiation in fight against early lung cancer
Disease control OngoingThis study is testing whether adding an immunotherapy drug (atezolizumab) to a precise form of radiation therapy works better than radiation alone for people with early-stage, non-small cell lung cancer who cannot have surgery. The goal is to see if the combination helps patients…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC
-
One-Two punch for lung cancer: can zapping tumors boost drug power?
Disease control OngoingThis study is for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). It tests if taking the targeted drug osimertinib for 6-12 weeks, then adding focused radiation therapy or surgery to remaining tumors, works better at keeping the…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Radiation boost for tough lung cancers: can it extend lives?
Disease control TerminatedThis study is for people with advanced non-small cell lung cancer that has low levels of a marker called PD-L1. It compares the standard immunotherapy treatment (with or without chemo) to the same treatment plus a short course of radiation. The goal is to see if adding radiation …
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Cancer treatment moves home: trial tests telemedicine for lung cancer care
Disease control OngoingThis study is testing whether a lung cancer immunotherapy drug can be safely and effectively given at home by a visiting nurse, with most doctor visits done remotely via video call. It involves patients with non-small cell lung cancer who are eligible for the drug atezolizumab. T…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Cancer patients get relief from harsh treatment side effects
Disease control OngoingThis study compares two drugs, infliximab and vedolizumab, to treat severe colon inflammation and diarrhea caused by cancer immunotherapy drugs. The trial involves 47 patients with melanoma, lung cancer, or urinary cancers who developed these side effects. Researchers aim to find…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
One-Shot radiation tested to zap remaining lung cancer cells
Disease control OngoingThis study is testing a new, faster way to give radiation after surgery for non-small cell lung cancer. Instead of weeks of daily treatments, doctors give one powerful, highly focused dose to try to kill any leftover cancer cells while aiming to spare healthy lung tissue. The mai…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New combo attack on tough lung cancer
Disease control OngoingThis early study is testing a two-part treatment for advanced non-small cell lung cancer with a specific genetic change (ALK). First, patients take a targeted drug (brigatinib) to shrink tumors. Then, they receive focused radiation or surgery to try to eliminate any remaining can…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Zapping lung cancer: heat vs. scalpel in Head-to-Head trial
Disease control OngoingThis study is comparing two standard ways to treat small lung tumors: a minimally invasive procedure that uses microwave energy to heat and destroy the tumor, and a small surgery to cut it out. Researchers want to see which method is safer, more effective at keeping the cancer fr…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New combo attack on tough lung cancers
Disease control OngoingThis study is testing a two-part treatment for patients with stage II or III non-small cell lung cancer who are not healthy enough for standard surgery or chemo-radiation. First, patients receive a shorter, more intense course of radiation. Then, they receive an immunotherapy dru…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
One-Two punch for lung cancer: can zapping tumors after immunotherapy extend lives?
Disease control OngoingThis study is for people with stage IV non-small cell lung cancer. It tests if adding local treatments like surgery or radiation to a two-drug immunotherapy regimen helps patients live longer than immunotherapy alone. The trial enrolled 339 patients who had not progressed after a…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Doctors test Immune-Boosting drugs with radiation to fight lung cancer
Disease control OngoingThis early-stage study is testing whether two immunotherapy drugs (ipilimumab and nivolumab) can be safely combined with radiation therapy for patients with stage II or III non-small cell lung cancer. The goal is to see if this combination helps the immune system attack the cance…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Cancer vaccine teams up with immune drugs in fight against advanced tumors
Disease control OngoingThis trial is testing whether combining an experimental cancer vaccine (CIMAvax) with approved immunotherapy drugs (nivolumab or pembrolizumab) is safe and more effective for treating advanced non-small cell lung cancer or squamous head and neck cancer. The study aims to find the…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Early trial aims to supercharge radiation for lung cancer
Disease control OngoingThis early-stage study is testing whether adding a drug called papaverine to a precise form of radiation therapy makes the treatment more effective for patients with non-small cell lung cancer or lung tumors that have spread. The main goal is to find the safest dose of papaverine…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New pill targets 'Undruggable' cancer mutation in advanced lung cancer
Disease control OngoingThis study is testing an experimental pill called AMG 510 for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The pill is designed to block this specific mutation, which can drive cancer growth, in patients whose cancer has wor…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Mar 10, 2026 12:52 UTC
-
New combo therapy aims to stop lung Cancer's comeback
Disease control TerminatedThis large study is testing if adding a new pill (AZD6738) to a standard immunotherapy drug (durvalumab) is better at keeping cancer from coming back in people with certain stages of non-small cell lung cancer. It's for patients who have already had chemotherapy and surgery, but …
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Feb 27, 2026 15:06 UTC
-
Can a cancer drug stop lung cancer before it starts?
Prevention OngoingThis study is testing whether the immunotherapy drug pembrolizumab can prevent lung cancer in people at high risk. It includes people with suspicious lung nodules that haven't grown or shrunk, and people who've had early-stage lung cancer treated before. Participants receive the …
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Apr 01, 2026 14:42 UTC
-
New tool aims to ease the stress of lung cancer treatment choices
Symptom relief OngoingThis study is testing a simple, easy-to-understand conversation tool designed to help people with non-small cell lung cancer. The tool aims to improve how patients and doctors talk about treatment options, making the decision-making process clearer and less stressful. Researchers…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: NA • Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Mar 30, 2026 14:29 UTC
-
Virtual nurse coaches aim to improve life after cancer
Symptom relief OngoingThis study is testing a telehealth program designed to help people who have finished treatment for early-stage lung or colorectal cancer. It compares a special coaching program that teaches self-management skills to standard educational materials. The goal is to see if the coachi…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE3 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Mar 23, 2026 15:17 UTC
-
New hope for cancer patients struggling to eat
Symptom relief OngoingThis study is testing whether a medication called anamorelin can help improve appetite and prevent weight loss in people with advanced lung cancer who have poor appetite. Researchers will compare anamorelin against a placebo (inactive pill) in 25 patients over 9 weeks. The study …
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Mar 16, 2026 15:25 UTC
-
Scans spot hidden heart damage from cancer treatment
Knowledge-focused OngoingThis study aims to find early signs of heart damage in cancer patients receiving radiation therapy to the chest. Researchers will use special heart scans and blood tests on 28 participants before, during, and after their radiation treatment. The goal is to learn how to identify p…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC
-
Can we predict who gets nerve damage from chemo?
Knowledge-focused OngoingThis study aims to create a tool to predict which cancer patients are most likely to develop nerve damage (like tingling or numbness in hands and feet) from a common class of chemotherapy drugs called taxanes. Researchers will follow over 1,300 patients with breast, lung, or ovar…
Matched conditions: LUNG NON-SMALL CELL CARCINOMA
Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC